CDK4 and breast carcinoma: We found that the correlations of sensitivity to the CDK4/6 inhibitors palbociclib and ribociclib with ENST00000547281 were significantly stronger than the correlations of sensitivity to the CDK4/6 inhibitors palbociclib and ribociclib with the CDK4 gene in breast cancer (Fig. 6a).